BWXT Medical Ltd. is a leading innovator in the field of nuclear medicine, dedicated to enhancing patient care through advanced medical technologies. The company specializes in the production and supply of critical radioisotopes, including Actinium-225, which plays a vital role in targeted alpha therapy for cancer treatment. With a commitment to safety, quality, and regulatory compliance, BWXT Medical collaborates with industry partners to ensure a reliable supply of medical isotopes for clinical trials and commercial applications. Under the leadership of President Vittorio Puppo, appointed in August 2024, BWXT Medical continues to drive innovation and excellence in nuclear medicine, contributing significantly to the healthcare community.
Peraton provides complete situational awareness and data-driven decision-making for a lifetime of health and benefit management for active Service Members and Veterans that adapts at the speed of battle and enables improved peacetime, expeditionary force and casualty care readiness and services for these heroes.
